Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and remains a major global health burden. According to the World Health Organization (WHO), over 35 million new cancer cases are projected by 2050, marking a 77% rise from 20 million cases in 2022. This escalating prevalence is driving advancements in HCC therapies, including targeted treatments, immunotherapies, and combination regimens. Growing focus on precision medicine, biomarker-based therapies, and improved diagnostic strategies is strengthening development. According to the hepatocellular carcinoma pipeline analysis by Expert Market Research, sustained R&D and clinical progress will support strong pipeline growth in the coming years.
-
Major companies involved in the hepatocellular carcinoma pipeline analysis include Akeso, Shanghai Henlius Biotech, and others.
-
Leading drugs currently in the pipeline include HLX13, HLX53, MT-303, and others.
-
Strong pipeline expansion is driven by rising clinical trial activity, rapid adoption of immunotherapies, and growing investment in targeted therapies, accelerating development progress and boosting treatment innovation in the coming years.
Report Coverage
The Hepatocellular Carcinoma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into hepatocellular carcinoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for hepatocellular carcinoma. The hepatocellular carcinoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The hepatocellular carcinoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with hepatocellular carcinoma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to hepatocellular carcinoma.
Read more about this report - Request a Free Sample
Hepatocellular Carcinoma Pipeline Outlook
Hepatocellular carcinoma is the most common primary liver cancer that develops due to chronic liver damage. It arises when long-term inflammation, cirrhosis, or viral hepatitis causes abnormal cellular changes, resulting in the uncontrolled growth of malignant liver cells. Over time, these changes drive progressive tumor formation, making early detection and timely intervention essential for improving patient outcomes and preventing advanced disease progression.
Hepatocellular carcinoma treatments include immunotherapy, targeted therapy, and locoregional interventions designed to control tumor growth, improve survival, and support patients with advanced or unresectable disease. Hepatocellular carcinoma treatments include immunotherapy, targeted therapy, and locoregional procedures designed to slow tumor progression, improve survival, and manage advanced or unresectable disease. Treatment strategies continue to evolve with new clinical evidence and regulatory advancements. In April 2025, the Food and Drug Administration significantly expanded therapeutic options by approving nivolumab with ipilimumab for first-line treatment of unresectable or metastatic hepatocellular carcinoma. This approval, based on positive overall survival and response outcomes from the CHECKMATE-9DW trial, strengthened the drug pipeline and highlighted the growing role of combination immunotherapies in improving patient care.
Hepatocellular Carcinoma Epidemiology
Hepatocellular carcinoma remains a major global concern, driven by rising incidence and significant mortality. According to A. Vogel et al., 2025, it accounts for over 900,000 new cases and nearly 80% of the global liver cancer burden. As per the World Health Organization, cancer cases are projected to increase by 77% by 2050, intensifying pressure on healthcare systems. According to Hepatocellular Carcinoma Epidemiology by Expert Market Research, hepatocellular carcinoma represents up to 85% of primary liver cancers, with India reporting an incidence of 2.15 per 100,000. These trends underscore the urgent need for innovative drug pipeline development.
Hepatocellular Carcinoma – Pipeline Therapeutic Assessment
This section of the report covers the analysis of hepatocellular carcinoma drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The hepatocellular carcinoma pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Gene Therapies
- Peptides
- Polymers
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
- Oral
- Parenteral
- Others
Hepatocellular Carcinoma Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 53%, covers a major share of the total hepatocellular carcinoma clinical trials, followed by phase I at 29%. Phase III contributes 12%. The strong presence of phase II and phase I candidates indicates a robust pipeline, promising significant advancements, increased treatment options, and potential growth in the hepatocellular carcinoma market.
Hepatocellular Carcinoma Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the hepatocellular carcinoma pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The hepatocellular carcinoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for hepatocellular carcinoma. Targeted therapy is gaining momentum in hepatocellular carcinoma treatment, focusing on receptor tyrosine kinases. For instance, ETN101, a multiple tyrosine kinase inhibitor targeting FLT3, KIT, VEGFR2, and PDGFR-beta, is under evaluation. Preclinical studies demonstrated its ability to inhibit tumor growth and induce partial or complete remission in models unresponsive to conventional therapies, offering potential new options for advanced HCC patients.
Hepatocellular Carcinoma Clinical Trials – Key Players
The EMR report for the hepatocellular carcinoma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed hepatocellular carcinoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in hepatocellular carcinoma clinical trials:
- Akeso
- Shanghai Henlius Biotech
- Pfizer
- Myeloid Therapeutics
- Etnova Therapeutics Corp.
- Hoffmann-La Roche
- Abivax S.A.
- Merck Sharp & Dohme LLC
- Bristol-Myers Squibb
- Beijing Gene Key Life Technology Co., Ltd.
- AstraZeneca
- Coherus Oncology, Inc.
- Biotheus Inc.
- AbbVie
Hepatocellular Carcinoma – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for hepatocellular carcinoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of hepatocellular carcinoma drug candidates.
Drug: HLX13
HLX13, an ipilimumab biosimilar administered intravenously, is being sponsored by Shanghai Henlius Biotech for this integrated Phase I/III trial. It is expected to be completed in 2028. The study is examining the efficacy, safety, immunogenicity, and pharmacokinetics of HLX13 compared with US- and EU-sourced YERVOY® in first-line treatment of unresectable hepatocellular carcinoma. HLX13 acts by blocking CTLA-4–mediated inhibitory signaling, enhancing T-effector cell activity, and potentially depleting tumour-site T-regulatory cells to strengthen antitumor immune responses.
Drug: HLX53
HLX53, an anti-TIGIT Fc fusion protein developed by Shanghai Henlius Biotech, is being evaluated in this Phase II trial sponsored by the company. The study is examining the optimal dosage and ongoing assessment of efficacy, safety, and tolerability when HLX53 is combined with Serplulimab (HLX10, an anti-PD-1 antibody) and HLX04, a bevacizumab biosimilar. HLX53 is designed to enhance immune response by blocking TIGIT and is administered intravenously. This trial is progressing toward its estimated completion in 2027, aiming to improve outcomes in untreated advanced hepatocellular carcinoma.
Drug: MT-303
MT-303 is an investigational, first-in-class GPC3-FcA-LNP therapy that is being administered intravenously to target GPC3-expressing advanced or metastatic cancers, including hepatocellular carcinoma. Developed by Myeloid Therapeutics, this Phase 1 study is examining the safety, tolerability, pharmacokinetics, and pharmacodynamics of MT-303 while determining its MTD and RP2D. The drug is designed to reprogram myeloid cells to attack tumors and stimulate a broader immune response by presenting tumor neoantigens. The trial is currently ongoing and is expected to be completed in 2026.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Hepatocellular Carcinoma Pipeline Insight Report
- Which companies/institutions are leading the hepatocellular carcinoma drug development?
- Which company is leading the hepatocellular carcinoma pipeline development activities?
- What is the current hepatocellular carcinoma commercial assessment?
- What are the opportunities and challenges present in the hepatocellular carcinoma pipeline landscape?
- What is the efficacy and safety profile of hepatocellular carcinoma pipeline drugs?
- Which company is conducting major trials for hepatocellular carcinoma drugs?
- Which companies/institutions are involved in hepatocellular carcinoma collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in hepatocellular carcinoma?
Reasons To Buy This Report
The Hepatocellular Carcinoma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for hepatocellular carcinoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into hepatocellular carcinoma collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share